Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.
about
Effect of Cytochrome b5 Content on the Activity of Polymorphic CYP1A2, 2B6, and 2E1 in Human Liver MicrosomesNADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.Cross-linking mass spectrometry and mutagenesis confirm the functional importance of surface interactions between CYP3A4 and holo/apo cytochrome b(5).The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients.Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.Cytochrome P450 variations in different ethnic populations.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
P2860
Q28547950-696A9E95-197F-4983-95EE-40D8A211F62CQ30537968-10F58A98-AE8F-4E72-A1D5-8F6D554657A7Q33821729-F7FAADFA-430D-4E96-95E5-900F10244C9EQ35846912-B837C0C9-E485-4E3B-8A25-18B542A4FF99Q35913104-4DD2BFAB-7FA5-419B-876B-A3D771B63396Q36562502-D73B3833-D91B-477A-83C6-4DB10ECFC983Q36598930-893C421D-2CD2-4882-B448-E890778E01B8Q37262064-BED9DB91-E82D-4126-9BE3-D9D5B872BBE4Q37325576-847E582D-77AA-43DB-9858-5FC21A822883Q37590883-0B2F6862-51FC-4D30-8A5A-08F09D9309FAQ37604428-25344660-9C7F-47A7-A07F-ADB1727B1C05Q37979866-3FB45583-65FF-4F2A-B78A-F53D040A85D9Q38130410-4945B5AC-1332-4B22-93B6-23FB86DC722CQ38684505-62F397D6-3B60-4B64-AEFF-5C81414B415DQ39444051-83A0BF93-4E0B-4F73-AA95-9AD5A894C569Q40793437-3C203541-CE99-43E9-9470-23DB4340CE74
P2860
Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Drug metabolism by CYP2C8.3 is ...... 0 reductase and cytochrome b5.
@ast
Drug metabolism by CYP2C8.3 is ...... 0 reductase and cytochrome b5.
@en
type
label
Drug metabolism by CYP2C8.3 is ...... 0 reductase and cytochrome b5.
@ast
Drug metabolism by CYP2C8.3 is ...... 0 reductase and cytochrome b5.
@en
prefLabel
Drug metabolism by CYP2C8.3 is ...... 0 reductase and cytochrome b5.
@ast
Drug metabolism by CYP2C8.3 is ...... 0 reductase and cytochrome b5.
@en
P2093
P2860
P1476
Drug metabolism by CYP2C8.3 is ...... 0 reductase and cytochrome b5.
@en
P2093
Eric A Evangelista
Kristin D Marciante
Rheem A Totah
Rüdiger Kaspera
Suresh B Naraharisetti
P2860
P304
P356
10.1016/J.BCP.2011.06.027
P407
P577
2011-06-24T00:00:00Z